NPS Pharmaceuticals’ Short Bowel Syndrome Treatment Shows Promise

Bedminster, N.J.-based NPS Pharmaceuticals completed a STEPS 2 study of Gattex, a treatment for patients with short bowel syndrome and found a large number of studied patients were able to completely or partially wean from parenteral support.

Advertisement

Gattex is an injection of a protein involved in the rehabilitation of the intestinal lining. Of the 88 patients studied, 13 had complete independence from parenteral support after using the treatment. Others had support volumes reduced or gained days off parenteral support.

Company representatives will present the results at the American College of Gastroenterology’s Annual Scientific Meeting and Postgraduate Course in San Diego this month.

More Articles on Gastroenterology:
RedHill Biopharma Seeks Patients for Phase III Crohn’s Disease Treatment Drug Trial
Kanawha Valley Gastroenterology Associates Selects Benchmark Systems EHR
Dr. Gurpreet Singh Joins Woodland Healthcare in California

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.